Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare
PE firm expands into selective control deals as it looks for opportunities in domestic formulations and API/CDMO
Attribution
This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.
Read on Business Today